| Route of Administration | Dosage Form / Strength/Composition | Non-medicinal Ingredients |
|---|---|---|
| Oral | Capsule 0.25 mg: Each capsule contains 0.363 mg talazoparib tosylate equivalent to 0.25 mg talazoparib free base. 1 mg: Each capsule contains 1.453 mg talazoparib tosylate equivalent to 1 mg talazoparib free base. | Silicified microcrystalline cellulose 0.25 mg capsule shell: hypromellose, titanium |
TALZENNA 0.25 mg capsules
Opaque, size #4 hard hypromellose (HPMC) capsule with an ivory cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 0.25” in black).
TALZENNA 1 mg capsules
Opaque, size #4 hard hypromellose (HPMC) capsule with a light red cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 1” in black).
| Route of Administration | Dosage Form / Strength/Composition | Non-medicinal Ingredients |
|---|---|---|
| Oral | Capsule 0.25 mg: Each capsule contains 0.363 mg talazoparib tosylate equivalent to 0.25 mg talazoparib free base. 1 mg: Each capsule contains 1.453 mg talazoparib tosylate equivalent to 1 mg talazoparib free base. | Silicified microcrystalline cellulose 0.25 mg capsule shell: hypromellose, titanium |
TALZENNA 0.25 mg capsules
Opaque, size #4 hard hypromellose (HPMC) capsule with an ivory cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 0.25” in black).
TALZENNA 1 mg capsules
Opaque, size #4 hard hypromellose (HPMC) capsule with a light red cap (printed with “Pfizer” in black) and a white body (printed with “TLZ 1” in black).
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: 1 866 723-7111.
To report an adverse event related to COMIRNATY, and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.